Amedica Announces Expansion Of Executive Team
Marketing, Sales, Legal and Compliance Executives Added to Promote Adoption of
the Company's Proprietary Silicon Nitride Technology
SALT LAKE CITY, Jan. 29, 2013
SALT LAKE CITY, Jan. 29, 2013 /PRNewswire/ -- Amedica Corporation, a spinal
and reconstructive medical device manufacturer, today announced several new
additions to its executive management team to help guide the company's efforts
as Amedica shifts the standard of care for interbody fusion devices toward
proprietary Silicon Nitride (SiN) ceramic. Four strategic appointments,
including a Senior Vice President of Market Development, Vice President of
Marketing, a Senior Vice President of Sales, and a Chief Legal and Compliance
Officer, have been added to the executive team to help execute on the
company's business objectives.
Amedica is focused on advancing medical applications of its proprietary
Silicon Nitride ceramic. In November 2007, Amedica secured clearance from the
U.S. Food and Drug Administration to manufacture and market Silicon
Nitride-based interbody fusion devices. The resulting Valeo^® product line was
launched in 2008 and has since been adopted by physicians across the country
as the premier interbody fusion device. In September 2012, Amedica announced
the expansion of biomaterial claims for its FDA 510(k) cleared Valeo Interbody
Fusion Devices. In recent studies published in peer-reviewed journals[i],[ii],
Silicon Nitride demonstrated anti-infective properties as well as superior new
bone formation and osteointegration in comparison to PEEK and titanium. Also
in September of 2012, Amedica received 510(k) clearance from the U.S. Food and
Drug Administration to market a second generation family of cervical and
lumbar interbody fusion devices. The company is also exploring innovative
solutions for orthopaedic implants.
"This is a momentous time for us as we expand our leadership team and gain
extensive expertise and insights to further execute on our business strategy.
Mr. Rupinskas, Mr. Sendro, Mr. Abraham, and Mr. Ontiveros bring a wealth of
experience to Amedica that will be critical to our ongoing success," said Eric
K. Olson, President and Chief Executive Officer, Amedica.
As Amedica works to expand the utilization of Silicon Nitride in other
orthopaedic applications, the hiring of experienced executives will be a key
to success. Vytas Rupinskas joins Amedica as Vice President of Marketing. Mr.
Rupinskas brings more than twenty five years of marketing experience in the
orthopedic, spinal and neuromodulation medical device markets previously
holding senior positions at St Jude Medical, DePuy Orthopedics, DePuy
International and DePuy Spine.
Paul Sendro, formerly Senior Vice President of Sales for Amedica, will now be
leading the company's strategic market development initiatives. Paul has over
20 years of experience in the orthopaedic, trauma and spine medical device
industries. He has held leadership positions at numerous well established
companies such as US Spine, Vertebron, Blackstone Medical, Stryker Inc. and
Jim Abraham joins Amedica as Senior Vice President of Sales bringing with him
over 25 years of experience in the orthopedic, trauma, spine, biologics and
dental markets. He comes to Amedica from Stryker Orthopedics and has
previously held a number of executive positions at companies such as IsoTis
Orthobiologics, Regeneration Technologies, Encore Orthopedics and
Kevin Ontiveros joins Amedica as Chief Legal and Compliance Officer. Kevin has
over 20 years of experience serving as in-house and outside corporate counsel
for publicly traded and privately held medical device and
biotechnology/pharmaceutical companies such as ImaRx Therapeutics, Inc. (IMRX)
and NPS Pharmaceuticals, Inc. (NPSP).
Detailed information about Amedica's Executive Management Team is available at
About Amedica Corporation:
Amedica is an innovative spine and orthopaedic implant and device
manufacturing and distribution company that provides advanced surgical
applications including silicon nitride ceramic technologies. The company's
platform technologies represent a new standard for implants and biologics
based on superior performance, safety and efficacy. Amedica is a privately
held, private equity backed company founded in 1996 by internationally
recognized orthopaedic surgeons and ceramicists. The company is ISO 13485
certified, its spine products are FDA cleared, CE marked, and sold in ten
countries. Amedica Corporation is based in Salt Lake City, UT.
Stacey Holifield / Stacy Nartker
[i] Gorth, Puckett, et al. "Decreased bacteria activity on Si3N4 surfaces
compared to PEEK or titanium," International Journal of Nanomedicine. 2012.7
(2012): 4829-4840. Print.
[ii] Webster, Patel, et al. "Anti-infective and osteointegration properties of
silicon nitride, poly (ether ether ketone), and titanium implants," Acta
Biomaterialia. 8.12 (2012): 4447–4454. Print.
SOURCE Amedica Corporation
Press spacebar to pause and continue. Press esc to stop.